公开(公告)号：US20100021468A1

公开(公告)日：2010-01-28

申请号：US12568134

申请日：2009-09-28

Applicant: Rong-Fu Wang ,  Steven A. Rosenberg ,  Gang Zeng

Inventor： Rong-Fu Wang ,  Steven A. Rosenberg ,  Gang Zeng

IPC: A61K39/395 ,  C07K14/705 ,  A61K38/17 ,  C07H21/04 ,  C12N15/63 ,  C12N5/10 ,  C07K16/28 ,  C12P21/02 ,  C12Q1/68 ,  G01N33/53 ,  A61K35/12 ,  C12N7/01 ,  A61K35/76 ,  A01K67/027 ,  C12N5/0783 ,  C07K7/06 ,  C07K7/08 ,  A61K31/7088 ,  A61K39/00

CPC classification number: A61K35/17 ,  A01K2217/05 ,  A61K38/00 ,  A61K38/08 ,  A61K39/00 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/53 ,  C07K7/06 ,  C07K14/4748 ,  C07K16/30 ,  C07K2319/00 ,  C12N2799/021 ,  Y02A50/412

Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.

Abstract translation: 本发明公开了鉴定和分离衍生自癌症抗原NY ESO-1的新型MHC II类表位。 来自NY-EsO-1的新型MHC II类表位以HLA II类限制性方式被识别，特别是HLA-DR或HLA-DP受限的CD4 + T淋巴细胞。 该基因的产物是用于预防，治疗和诊断癌症患者的免疫治疗策略的有希望的候选者。

公开(公告)号：US07619057B2

公开(公告)日：2009-11-17

申请号：US10182506

申请日：2001-01-26

Applicant: Rong-Fu Wang ,  Steven A Rosenberg ,  Gang Zeng

Inventor： Rong-Fu Wang ,  Steven A Rosenberg ,  Gang Zeng

IPC: C07K5/10

CPC classification number: A61K35/17 ,  A01K2217/05 ,  A61K38/00 ,  A61K38/08 ,  A61K39/00 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/53 ,  C07K7/06 ,  C07K14/4748 ,  C07K16/30 ,  C07K2319/00 ,  C12N2799/021 ,  Y02A50/412

Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.

Abstract translation: 本发明公开了鉴定和分离衍生自癌症抗原NY ESO-1的新型MHC II类表位。 来自NY-EsO-1的新型MHC II类表位以HLA II类限制性方式被识别，特别是HLA-DR或HLA-DP受限的CD4 + T淋巴细胞。 该基因的产物是用于预防，治疗和诊断癌症患者的免疫治疗策略的有希望的候选者。

公开(公告)号：US07015312B1

公开(公告)日：2006-03-21

申请号：US09571313

申请日：2000-05-16

Applicant: Rong-Fu Wang ,  Steven A. Rosenberg

Inventor： Rong-Fu Wang ,  Steven A. Rosenberg

IPC: C07K16/00

CPC classification number: A61K39/0011 ,  A61K2039/5158

Abstract: The present invention discloses that the normal melanogenic gene, gp75 gene, encodes a gene product, a 24 amino acid peptide of ORF3, which is processed to an antigenic cancer peptide recognized by T lymphocytes. The cancer peptide of the invention derived from ORF3 is recognized by cancer antigen specific T lymphocytes as a tumor rejection antigen. The products of this gene are promising candidates for immunotherapeutic strategies for the treatment and diagnosis of patients with cancer.

Abstract translation: 本发明公开了正常的黑素生成基因gp75基因，编码基因产物，ORF3的24个氨基酸的肽，被加工成由T淋巴细胞识别的抗原性癌肽。 衍生自ORF3的本发明的癌肽被癌抗原特异性T淋巴细胞识别为肿瘤排斥抗原。 该基因的产物是用于癌症患者的治疗和诊断的免疫治疗策略的有希望的候选者。

公开(公告)号：US6132980A

公开(公告)日：2000-10-17

申请号：US161877

申请日：1998-09-28

Applicant: Rong Fu Wang ,  Steven A. Rosenberg

Inventor： Rong Fu Wang ,  Steven A. Rosenberg

IPC: C12N15/09 ,  A01K67/027 ,  A61K31/00 ,  A61K35/14 ,  A61K35/76 ,  A61K38/00 ,  A61K39/00 ,  A61K39/385 ,  A61K45/08 ,  A61K48/00 ,  A61P35/00 ,  C07H21/00 ,  C07K7/06 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/30 ,  C12N5/08 ,  C12N5/10 ,  C12N7/00 ,  C12N9/00 ,  C12N9/02 ,  C12N9/90 ,  C12N15/12 ,  C12N15/52 ,  C12N15/53 ,  C12P21/02 ,  C12Q1/02 ,  C12Q1/68 ,  C12R1/91 ,  G01N33/531 ,  G01N33/554 ,  G01N33/574

CPC classification number: C12N9/0059 ,  C07K14/4748 ,  C12N9/0071 ,  C12N9/90 ,  A01K2217/05 ,  A61K2039/51 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  C12N2799/021 ,  Y10S435/96 ,  Y10S435/975 ,  Y10S530/828

Abstract: The infusion of TIL586 along with interleukin-2 (IL-2) into the autologous patient with metastatic melanoma resulted in the objective regression of tumor. A gene encoding a tumor antigen recognized by TIL586 was previously isolated and shown to encode gp75 or TRP-1. The present invention relates to the identification of a second tumor antigen recognized by a HLA-A31 restricted CTL clone derived from the TIL586 cell line. This antigen derived from the TRP-2 protein tumor antigen and peptides thereof are capable of sensitizing target cells for lysis by a CTL clone at 1 nM peptide concentration. Modified peptides were also recognized by the CTL clone.

Abstract translation: 将TIL586与白细胞介素-2（IL-2）一起输入到具有转移性黑素瘤的自体患者中，导致肿瘤的客观消退。 先前分离了编码TIL586识别的肿瘤抗原的基因，并显示编码gp75或TRP-1。 本发明涉及由来自TIL586细胞系的HLA-A31限制性CTL克隆识别的第二种肿瘤抗原的鉴定。 衍生自TRP-2蛋白质肿瘤抗原的抗原及其肽能够以1nM肽浓度通过CTL克隆致敏靶细胞以进行裂解。 修饰的肽也被CTL克隆识别。

公开(公告)号：US5840839A

公开(公告)日：1998-11-24

申请号：US599602

申请日：1996-02-09

Applicant: Rong-Fu Wang ,  Steven A. Rosenberg

Inventor： Rong-Fu Wang ,  Steven A. Rosenberg

IPC: C12N15/09 ,  A01K67/027 ,  A61K31/00 ,  A61K35/14 ,  A61K35/76 ,  A61K38/00 ,  A61K39/00 ,  A61K39/385 ,  A61K45/08 ,  A61K48/00 ,  A61P35/00 ,  C07H21/00 ,  C07K7/06 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/30 ,  C12N5/08 ,  C12N5/10 ,  C12N7/00 ,  C12N9/00 ,  C12N9/02 ,  C12N9/90 ,  C12N15/12 ,  C12N15/52 ,  C12N15/53 ,  C12P21/02 ,  C12Q1/02 ,  C12Q1/68 ,  C12R1/91 ,  G01N33/531 ,  G01N33/554 ,  G01N33/574

CPC classification number: C12N9/0059 ,  C07K14/4748 ,  C12N9/0071 ,  C12N9/90 ,  A01K2217/05 ,  A61K2039/51 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  C12N2799/021 ,  Y10S435/96 ,  Y10S435/975 ,  Y10S530/828

Abstract: The present invention discloses that the normal melanogenic gene, gp75 gene, encodes a gene product, a 24 amino acid peptide of ORF3, which is processed to an antigenic cancer peptide recognized by T lymphocytes. The cancer peptide of the invention derived from ORF3 is recognized by cancer antigen specific T lymphocytes as a tumor rejection antigen. The products of this gene are promising candidates for immunotherapeutic strategies for the treatment and diagnosis of patients with cancer.